Sentinel node biopsy in cutaneous melanoma patients with germline CDKN2A mutations.

pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial. Lancet Oncol 2017; 18:464–472. 3 Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med 2019; 381:626–636. 4 Gil S, Goetgheluck J, Paci A, Broutin S, Friard S, Couderc LJ, et al. Efficacy and safety of gefitinib during pregnancy: case report and literature review. Lung Cancer 2014; 85:481–484. 5 Angrisani L, Santonicola A, Iovino P, Vitiello A, Zundel N, Buchwald H, Scopinaro N. Bariatric surgery and endoluminal procedures: IFSO worldwide survey 2014. Obes Surg 2017; 27:2279–2289.

[1]  S. Puig,et al.  Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations , 2018, Journal of Medical Genetics.

[2]  D. Schadendorf,et al.  Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma , 2018, The New England journal of medicine.

[3]  K. Nielsen,et al.  Germline CDKN2A Mutation Status and Survival in Familial Melanoma Cases. , 2016, Journal of the National Cancer Institute.

[4]  N. Hayward,et al.  Melanoma genetics , 2015, Journal of Medical Genetics.

[5]  R. Elashoff,et al.  Final trial report of sentinel-node biopsy versus nodal observation in melanoma. , 2014, The New England journal of medicine.